Sunday 18 October 2026 Export MCRB’s income statement to Excel — free account

Seres Therapeutics, Inc.

In the quarter to June 2026, revenue grew 96.8%, EPS grew 120.7% and free cash flow fell 66.2%, each against the same quarter a year earlier.

2.46 0.07 −2.77%

Follow MCRB

Alert me

Market cap: $25.2M
P/E: 0.0×
Fwd P/E: −0.7×
Dividend yield: —
F-score: n/a
Altman Z: −10.99
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.05

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	4	—	—	4	—	—	4	—	—	4	—	—

Insider Ownership 22.32%

Capital & Financial Ratios $m

Market Cap 25.15

Revenue 1.88

Net Income (22.46)

Free Cash Flow (51.25)

Net Debt (15.59)

Current Ratio 2.11

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.72)

P/S ratio 12.68

P/B ratio 0.69

Past 5Y EPS Growth —

This Y EPS Growth (649.09%)

Next Y EPS Growth (40.71%)

Next Y revenue growth 1,649.05%

Next 5Y EPS Growth 25.41%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 60.79%

10-year low 10-year high

P/B against its own 10 years 0.11%

10-year low 10-year high

EV/Sales against its own 10 years 82.41%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	128	31	46	16
Receivables	9	2	1	25
Inventory	—	—	—	—
Other	—	—	—	—
	175	39	49	42

	2023	2024	2025	Q'26
Payables	4	4	2	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	99	41	19	20

Compound Annual Growth %

	10y	5y	3y
Sales	—	(53.03%)	(82.41%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(14.24%)	(24.03%)	60.06%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	1	—	—	—
’25	—	—	0	0	1
’23	(1)	126	0	0	126
’22	1	1	3	1	7
’21	6	5	127	7	145
’20	8	6	1	18	33
’19	7	13	7	8	35

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(22)	—	—	—
’25	27	(13)	2	(15)	1
’24	(35)	(40)	(35)	(39)	(149)
’23	(77)	66	(59)	(47)	(117)
’22	(66)	(50)	(60)	(53)	(229)
’21	(29)	(40)	128	(52)	7
’20	(24)	(26)	(26)	(18)	(94)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(22)	—	—	—
’25	27	(13)	2	(15)	1
’24	(35)	(40)	(35)	(39)	(149)
’23	(81)	65	(61)	(48)	(125)
’22	(69)	(52)	(61)	(56)	(239)
’21	(31)	(42)	124	(53)	(3)
’20	(24)	(26)	(26)	(18)	(94)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.08)	0.47	—	—	—
’25	3.75	(2.27)	0.94	(1.76)	0.64
’24	(5.40)	(4.40)	11.60	(1.78)	0.00
’23	(11.40)	7.20	(7.40)	(6.40)	(17.80)
’22	(12.20)	(14.00)	(9.80)	(10.80)	(46.20)
’21	(7.80)	(10.60)	14.40	(11.00)	(14.40)
’20	(5.60)	(5.60)	(7.20)	(3.60)	(22.40)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	161.00	177.00	90.40	40.40	50.40	108.20	50.00	18.20	10.80	6.53	Analyst estimates 2026–2028 Powerpack
	High	719.60	348.40	226.90	167.80	770.00	598.00	189.80	137.40	41.00	29.98
People
People	Employees	127	138	145	108	155	333	431	160	103	66
	Revenue/emp, $m	0.17	0.23	0.19	0.32	0.21	0.44	0.02	0.79	0.00	0.01
Income, $m
Income, $m	Revenue	22	32	28	35	33	145	7	126	—	1
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	—	100.00
	EBT	(92)	(89)	(99)	(70)	(89)	(66)	(184)	(190)	(126)	6
	EBT margin, %	(420.74)	(278.44)	(350.03)	(203.68)	(268.33)	(45.25)	(2,575.49)	(150.51)	0.00	721.93
	Net income	(92)	(89)	(99)	(70)	(89)	(66)	(250)	(114)	0	6
	Depreciation	4	7	8	8	8	9	8	7	7	4
Per share, $
Per share, $	Revenue	10.92	15.87	13.88	12.18	8.33	31.61	1.32	19.74	0.00	0.09
	Earnings	(46.00)	(44.20)	(48.60)	(24.80)	(22.40)	(14.40)	(46.20)	(17.80)	0.00	0.64
	Cash flow	22.04	(37.34)	(30.85)	(27.01)	(23.46)	1.46	(42.34)	(18.34)	(19.13)	0.13
	Capex	(10.79)	(2.31)	(0.95)	(0.35)	(0.15)	(2.09)	(1.82)	(1.25)	(0.05)	0.00
	Free cash flow	11.26	(39.65)	(31.80)	(27.37)	(23.61)	(0.63)	(44.16)	(19.58)	(19.17)	0.12
	Book value	66.57	30.01	(23.58)	(17.06)	43.80	28.68	2.00	(7.01)	1.77	4.99
	Shares, m	2	2	2	3	4	5	5	6	8	9
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	22.21
	P/S	18.33	13.29	6.52	5.66	58.85	5.27	81.88	1.42	—	89.49
	P/B	3.01	7.03	0.00	0.00	11.19	5.81	54.12	0.00	—	2.98
	EV/Sales	9.94	8.90	3.72	3.63	51.96	3.44	63.53	1.21	—	128.00
	EV/FCF	9.65	(3.56)	(1.62)	(1.62)	(18.32)	(172.98)	(1.90)	(1.22)	—	175.40
Cash, $m
Cash, $m	Operating cash flow	44	(76)	(63)	(77)	(94)	7	(229)	(117)	(149)	1
	Capex	(21)	(5)	(2)	(1)	(1)	(10)	(10)	(8)	0	0
	Free cash flow	22	(80)	(65)	(78)	(94)	(3)	(239)	(125)	(149)	1
Balance, $m
Balance, $m	Working capital	168	123	51	54	222	221	109	77	(3)	30
	Total debt	11	9	7	25	25	25	51	102	—	—
	Net debt	(183)	(141)	(79)	(70)	(229)	(266)	(131)	(26)	(31)	(46)
	Shareholders’ equity	133	61	(48)	(48)	175	132	11	(45)	14	44
Returns, %
Returns, %	ROA	(37.41)	(38.68)	(63.83)	(55.58)	(37.50)	(18.80)	(71.10)	(32.15)	0.05	4.10
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(54.18)	(92.46)	(1,563.81)	145.85	(140.99)	(42.83)	(351.62)	667.53	(0.88)	19.64

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IBO Impact Biomedical Inc.	$27.0M	0.2×	—	−57.14% (below 0%: shrinking)	n/m	+167.72% (above 0%: growing)	66.67%	(23,400.00%)	Compare
ATOS Atossa Therapeutics, Inc.	$26.4M	— (loss-making)	—	−94.28% (below 0%: shrinking)	n/m	−32.86% (below 0%: shrinking)	0.00%	0.00%	Compare
IGC IGC Pharma, Inc.	$26.3M	— (loss-making)	— (loss-making)	−19.70% (below 0%: shrinking)	n/m	−103.33% (below 0%: shrinking)	18.11%	(1,050.57%)	Compare
MCRB Seres Therapeutics, Inc.	$25.2M	— (loss-making)	— (loss-making)	+96.79% (above 0%: growing)	n/m	−66.15% (below 0%: shrinking)	100.00%	(2,890.35%)
ABVC ABVC BioPharma, Inc.	$24.9M	— (loss-making)	— (loss-making)	+66,233.33% (above 0%: growing)	n/m	+72.66% (above 0%: growing)	100.00%	0.00%	Compare
BYSI BeyondSpring Inc.	$23.9M	— (loss-making)	— (loss-making)	+87.78% (above 0%: growing)	n/m	+35.78% (above 0%: growing)	100.00%	0.00%	Compare
CYAD Celyad SA	$23.8M	— (loss-making)	— (loss-making)	—	n/m	+78.72% (above 0%: growing)	0.00%	0.00%	Compare
PLRZ Polyrizon Ltd.	$23.7M	—	—	—	—	−744.51% (below 0%: shrinking)	—	—	Compare
IMMP Prima BioMed Ltd	$23.7M	— (loss-making)	—	—	n/m	−589,653.13% (below 0%: shrinking)	100.00%	(101.89%)	Compare
Median of peers	$24.4M	—	—	−19.70%	—	+1.46%	66.67%	0.00%

All 614 Biotechnology stocks →

Seres Therapeutics, Inc. (MCRB) key facts

Seres Therapeutics, Inc. (MCRB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MCRB traded at $2.46, a market capitalization of $25.2 million.
Return on equity was 19.6% and debt-to-equity 0.00.
Its Altman Z-score is −10.99 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.